BACKGROUND: Insulin requirements to maintain normoglycemia during glucocorticoid therapy and stress are often difficult to estimate. To simulate insulin resistance during stress, adults with type 1 diabetes mellitus (T1DM) were given a three-day course of prednisone. METHODS: Ten patients (7 women, 3 men) using continuous subcutaneous insulin infusion pumps wore the Medtronic Minimed CGMS (Northridge, CA) device. Mean (standard deviation) age was 43.1 (14.9) years, body mass index 23.9 (4.7) kg/m(2), hemoglobin A1c 6.8% (1.2%), and duration of diabetes 18.7 (10.8) years. Each patient wore the CGMS for one baseline day (day 1), followed by three days of self-administered prednisone (60 mg/dl; days 2-4), and one post-prednisone day (day 5). RESULTS: Analysis using Wilcoxon signed rank test (values are median [25th percentile, 75th percentile]) indicated a significant difference between day 1 and the mean of days on prednisone (days 2-4) for average glucose level (110.0 [81.0, 158.0] mg/dl vs 149.2 [137.7, 168.0] mg/dl; p = .022), area under the glucose curve and above the upper limit of 180 mg/dl per day (0.5 [0, 8.0] mg/dl.d vs 14.0 [7.7, 24.7] mg/dl.d; p = .002), and total daily insulin dose (TDI) , (0.5 [0.4, 0.6] U/kg.d vs 0.9 [0.8, 1.0] U/kg.d; p = .002). In addition, the TDI was significantly different for day 1 vs day 5 (0.5 [0.4, 0.6] U/kg.d vs 0.6 [0.5, 0.8] U/kg.d; p = .002). Basal rates and insulin boluses were increased by an average of 69% (range: 30-100%) six hours after the first prednisone dose and returned to baseline amounts on the evening of day 4. CONCLUSIONS: For adults with T1DM, insulin requirements during prednisone induced insulin resistance may need to be increased by 70% or more to normalize blood glucose levels.
BACKGROUND:Insulin requirements to maintain normoglycemia during glucocorticoid therapy and stress are often difficult to estimate. To simulate insulin resistance during stress, adults with type 1 diabetes mellitus (T1DM) were given a three-day course of prednisone. METHODS: Ten patients (7 women, 3 men) using continuous subcutaneous insulin infusion pumps wore the Medtronic Minimed CGMS (Northridge, CA) device. Mean (standard deviation) age was 43.1 (14.9) years, body mass index 23.9 (4.7) kg/m(2), hemoglobin A1c 6.8% (1.2%), and duration of diabetes 18.7 (10.8) years. Each patient wore the CGMS for one baseline day (day 1), followed by three days of self-administered prednisone (60 mg/dl; days 2-4), and one post-prednisone day (day 5). RESULTS: Analysis using Wilcoxon signed rank test (values are median [25th percentile, 75th percentile]) indicated a significant difference between day 1 and the mean of days on prednisone (days 2-4) for average glucose level (110.0 [81.0, 158.0] mg/dl vs 149.2 [137.7, 168.0] mg/dl; p = .022), area under the glucose curve and above the upper limit of 180 mg/dl per day (0.5 [0, 8.0] mg/dl.d vs 14.0 [7.7, 24.7] mg/dl.d; p = .002), and total daily insulin dose (TDI) , (0.5 [0.4, 0.6] U/kg.d vs 0.9 [0.8, 1.0] U/kg.d; p = .002). In addition, the TDI was significantly different for day 1 vs day 5 (0.5 [0.4, 0.6] U/kg.d vs 0.6 [0.5, 0.8] U/kg.d; p = .002). Basal rates and insulin boluses were increased by an average of 69% (range: 30-100%) six hours after the first prednisone dose and returned to baseline amounts on the evening of day 4. CONCLUSIONS: For adults with T1DM, insulin requirements during prednisone induced insulin resistance may need to be increased by 70% or more to normalize blood glucose levels.
Authors: G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: B Landis; L Jovanovic; E Landis; C M Peterson; S Groshen; K Johnson; N E Miller Journal: Diabetes Care Date: 1985 Nov-Dec Impact factor: 19.112
Authors: Daniel A Finan; Francis J Doyle; Cesar C Palerm; Wendy C Bevier; Howard C Zisser; Lois Jovanovic; Dale E Seborg Journal: J Diabetes Sci Technol Date: 2009-09-01
Authors: Wendy C Bevier; Serena M Fuller; Ryan P Fuller; Richard R Rubin; Eyal Dassau; Francis J Doyle; Lois Jovanovič; Howard C Zisser Journal: Diabetes Technol Ther Date: 2014-05-08 Impact factor: 6.118
Authors: Neda Rasouli; Stacey Seggelke; Joanna Gibbs; R Matthew Hawkins; Matthew L Casciano; Elizabeth Cohlmia; Jennifer Taylor-Cousar; Cecilia Wang; Rocio Pereira; Elisa Hsia; Boris Draznin Journal: J Diabetes Sci Technol Date: 2012-09-01
Authors: Boris Draznin; Janice Gilden; Sherita H Golden; Silvio E Inzucchi; David Baldwin; Bruce W Bode; Jeffrey B Boord; Susan S Braithwaite; Enrico Cagliero; Kathleen M Dungan; Mercedes Falciglia; M Kathleen Figaro; Irl B Hirsch; David Klonoff; Mary T Korytkowski; Mikhail Kosiborod; Lillian F Lien; Michelle F Magee; Umesh Masharani; Gregory Maynard; Marie E McDonnell; Eti S Moghissi; Neda Rasouli; Daniel J Rubin; Robert J Rushakoff; Archana R Sadhu; Stanley Schwartz; Jane Jeffrie Seley; Guillermo E Umpierrez; Robert A Vigersky; Cecilia C Low; Deborah J Wexler Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112